Dr. Reddys Laboratories Ltd.

Dr Reddys is currently trading at Rs. 2828.00, up by 25.45 points or 0.91% from its previous closing of Rs. 2802.55 on the BSE.

The scrip opened at Rs. 2815.00 and has touched a high and low of Rs. 2852.50 and Rs. 2815.00 respectively. So far 6133 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2939.80 on 28-Feb-2014 and a 52 week low of Rs. 1732.75 on 28-Mar-2013.

Last one week high and low of the scrip stood at Rs. 2939.80 and Rs. 2760.10 respectively. The current market cap of the company is Rs. 48140.81 crore.

The promoters holding in the company stood at 25.52% while Institutions and Non-Institutions held 40.90% and 16.48% respectively. Dr. Reddy's Laboratories has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox (moxifloxacin HCI) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The Avelox tablets brand had U.S. sales of approximately $195 million for the most recent twelve months ending in December 2013 according to IMS Health.

Dr. Reddy's Moxifloxacin Hydrochloride Tablets, 400 mg is available in bottle counts of 30.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.